Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Abstract Background Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription thr...

Full description

Bibliographic Details
Main Authors: Manon Belhassen, Faustine Dalon, Maëva Nolin, Eric Van Ganse
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Respiratory Research
Subjects:
Idiopathic pulmonary fibrosis
Antifibrotics
Mortality
Acute hospitalisations
Online Access:https://doi.org/10.1186/s12931-021-01714-y

Internet

https://doi.org/10.1186/s12931-021-01714-y

Similar Items